[O5] Oral Session 5　Breast Cancer
【E】

[O5-5] Trastuzumab Deruxtecan in Patients with HER2+ Metastatic BC: Updated Survival Results from a Ph2 Study, DESTINY-Breast01

^○Toshinari Yamashita¹, Shanu Modi², Ian Krop³, Yeon Hee Park⁴, Sung-Bae Kim⁵, Kenji Tamura⁶, Fabrice Andre⁷, Hiroji Iwata⁸, Yoshinori Ito⁹, Junji Tsurutani¹⁰, Joohyuk Sohn¹¹, Caleb Lee¹², Yali Liu¹², Jillian Cathcart¹², Jasmeet Singh¹², Cristina Saura¹³ (1.Kanagawa Cancer Center, Kanagawa, Japan, 2.Memorial Sloan Kettering Cancer Center, New York, NY, USA, 3.Dana-Farber Cancer Institute, Boston, MA, USA, 4.Samsung Medical Center, Seoul, South Korea, 5.Asan Medical Center, Seoul, South Korea, 6.Shimane University Hospital, Shimane, Japan, 7.Gustave Roussy, Villejuif, France, 8.Aichi Cancer Center Hospital, Aichi, Japan, 9.Nippon Medical School, Tokyo, Japan, 10.Showa University, Tokyo, Japan, 11.Yonsei Cancer Center, Seoul, South Korea, 12.Daiichi Sankyo, Inc., Basking Ridge, NJ, USA, 13.Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain)